RNS Announcements

Notice of Annual General Meeting - Clarification

05 June 2025

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, announces, for the avoidance of doubt, that Resolution 3 in the Company's Notice of Annual General Meeting is for the re-election of Steen Andersen, the Company's Chief Executive Officer, as a Director of the Company. The reference to Steen "Anderson" is a typographical error. Existing Forms of proxy for use at the Annual General Meeting remain valid.

 

For further information, please contact:

ProBiotix Health plc

https://probiotixhealth-ir.com/

 

[email protected]

Steen Andersen, Chief Executive Officer

Miles Nolan, Investor Relations

 



Peterhouse Capital Limited

Aquis Corporate Adviser and Broker

 

 

 

Mark Anwyl

Duncan Vasey

Tel: 020 7469 0930

 

Notes to Editors:

ProBiotix is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.

The Company has a unique approach: discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.

back to RNS & Investor News